MINNEAPOLIS--(BUSINESS WIRE)--In 2012, Dr. Jafar Golzarian performed the first prostate artery embolization (PAE) in the U.S. Today, he is confidently performing PAE on an outpatient basis at North ...

Prostate cancer is a leading cause of cancer-related death among men in the United States. Despite this, widespread adoption of prostate cancer screening has been controversial. Many primary care ...

After skin cancer, prostate cancer is the most common cancer among men in the U.S., and 20% to 30% of men who beat it once will face a recurrence within five years. A new treatment, known as salvage ...

TORONTO, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (PROF) (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets ...

SAN JOSE, Calif., July 23, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics (PRCT) ® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company dedicated to advancing patient care through ...

A groundbreaking, hour-long procedure using electrical currents to eliminate hard-to-reach prostate tumors is providing ...

iTIND, known as a Temporarily Implanted Nitinol Device, is a new procedure available for men who suffer from Benign Prostatic Hyperplasia (BPH), a non-cancerous condition where the prostate becomes ...

The journey through prostate cancer treatment marks a significant chapter in many men’s lives, with surgery often serving as a pivotal turning point toward recovery. While the removal of cancerous ...

This story is sponsored by Revere Health. Holmium Laser Enucleation of the Prostate (HoLEP) is rapidly becoming the gold standard surgical treatment for benign prostatic hyperplasia (BPH), and there ...